SARS-CoV-2 vaccines and myocarditis
- PMID: 37775180
- PMCID: PMC10541288
- DOI: 10.7861/clinmed.2023-0049
SARS-CoV-2 vaccines and myocarditis
Abstract
The development of safe and effective vaccines against severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) was a major turning point in the fight against the Coronavirus 2019 (COVID-19) pandemic. However, pharmacovigilance has revealed a small but significant incidence of cardiac inflammation manifesting clinically as myocarditis or pericarditis, particularly in younger vaccine recipients. The incidence is the highest among men under age 40 within a week of receiving the second dose of the mRNA vaccine. In this review, we summarise the evidence for, and guidelines in relation to, SARS-CoV2 vaccine-related myocarditis.
Keywords: COVID-19; SARS-CoV-2 vaccine-related myocarditis; mRNA vaccine; myocarditis; vaccine safety.
© Royal College of Physicians 2023. All rights reserved.
References
-
- Medicine and Healthcare Products Regulatory Agency. Coronavirus vaccine - summary of Yellow Card reporting. www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-... [Accessed 1 August 2023].
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous